Reviews rolling in for new Apple Watch, ECG app

The reviews are beginning to roll in for the new Apple Watch Series 4, which features an application that allows users to take their own electrocardiogram (ECG) reading.

Apple introduced its latest watch during an event on Sept. 12 in Cupertino, California. Among its many features, the fourth-generation watch is 30 percent larger, has an extended battery life and an FDA-approved ECG app.

Below are several reviews about Apple’s latest watch and its ECG feature.

In a New York Times review of the watch, technology writer Brian Chen said though the ECG feature isn’t as comprehensive as a traditional electrocardiograph, it’s helpful for people with heart problems.

“The new Apple Watch is perhaps one of the most significant developments in wearable gadgets in years. People with heart problems can easily use the EKG app to take electrocardiograms whenever they sense something abnormal, without the rigmarole I went through,” Chen wrote. “And the data can be shared immediately with their doctor, which could open a conversation about next steps, like going in for a visit or modifying treatment.”

A review in Women’s Health magazine said the “heart rate sensor functionality is legit.”

“Roughly a year and a half in the making, this ECG functionality is approved by the American Heart Association as well as the Food and Drug Administration, which is a very big deal,” the report said.

In a USA Today review, tech columnist Edward Baig wondered how people would respond to the new app.

“I question how this will work with real people in the real world. Will there be a high incidence of false positives? Will consumers even understand the results? The onus is on Apple to make this simple and to explain it in terms that won't freak watch wearers out,” Baig wrote.

""

Danielle covers Clinical Innovation & Technology as a senior news writer for TriMed Media. Previously, she worked as a news reporter in northeast Missouri and earned a journalism degree from the University of Illinois at Urbana-Champaign. She's also a huge fan of the Chicago Cubs, Bears and Bulls. 

Around the web

Heartflow, known for its AI-based CCTA evaluations, appears to be going public. The news follows years of momentum for the California-based company, including improved Medicare reimbursements for cardiac CT and a new Category I CPT code for its Plaque Analysis software.

Suman Tandon, MD, an American Society of Nuclear Cardiology board member, explains the group's call on Congress to update a number of healthcare policies. 

The 2026 MPFS proposed rule includes higher conversion factors across the board. However, some cardiology groups remain concerned about a series of reimbursement reductions for high-value cardiology services.